A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Pullback

NodeGuardian

2026-03-23 07:15:20

Abstract generation in progress

Vertex Pharmaceuticals (VRTX) has seen its share price pull back recently, declining about 5% over the last month and 1% over the past three months. Despite this, the stock is considered 23.3% undervalued by Vestra’s narrative, with a fair value of $592 compared to its current price of $454. This valuation is based on a 32x Forward P/E multiple applied to projected FY2027 Adjusted EPS, reflecting a transition to a multi-franchise leader, though the narrative highlights key risks related to the performance of non-CF revenue and renal programs.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.